Home West Coast San Diego, CA Alterome Therapeutics COMPANY
Clinical Phase 1
1 open job · last seen Oct 23, 2026 · 3 sources
Keywords: oncology small molecule Breast Cancer Endometrial Cancer PDAC - Pancreatic Ductal Adenocarcinoma NSCLC (Non-small Cell Lung Cancer) CRC (Colorectal Cancer) ALTA2618 ALTA3263 Show all 9 keywords
Location: San Marcos, CA · source · Oct 13, 2026
Profile checked Oct 10, 2026
At a glance HQ San Marcos, CA source Region West Coast Stage Clinical Phase 1 Latest trial Phase 1: A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutatio… (Mar 5, 2025) source Timeline Oct 8, 2026 Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗ Mar 5, 2025 Trial start Phase 1: A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations source ↗ Aug 22, 2024 Trial start Phase 1: A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors source ↗ Upcoming milestones Dec 29, 2026 (ESTIMATED) · Phase 1 · A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors · NCT06533059 2029-05 (ESTIMATED) · Phase 1 · A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations · NCT06835569 Estimated primary completion per ClinicalTrials.gov. Dates move.
Open jobs 1 Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Clinical trials (lead sponsor) 2 Record Title Phase Status Start Primary completion NCT06533059 A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors Phase 1 Active, not recruiting Aug 22, 2024 Dec 29, 2026 (estimated) NCT06835569 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations Phase 1 Recruiting Mar 5, 2025 2029-05 (estimated)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗ Connect See your connections at Alterome Therapeutics on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-18
